Modality
mRNA
MOA
TROP-2 ADC
Target
AHR
Pathway
RAS/MAPK
PsoriasisRett
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
~Oct 2019
→ ~Jan 2021
Phase 3
~Apr 2021
→ ~Jul 2022
NDA/BLA
Oct 2022
→ Mar 2031
NDA/BLACurrent
NCT08747964
1,024 pts·Psoriasis
2022-10→2027-10·Terminated
NCT06681941
1,587 pts·Rett
2024-04→2031-03·Not yet recruiting
2,611 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-161.5y awayPh3 Readout· Psoriasis
2031-03-265.0y awayPh3 Readout· Rett
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
NDA/BLA
Termina…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2027-10-16 · 1.5y away
Psoriasis
Ph3 Readout
2031-03-26 · 5.0y away
Rett
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08747964 | NDA/BLA | Psoriasis | Terminated | 1024 | UPDRS |
| NCT06681941 | NDA/BLA | Rett | Not yet recr... | 1587 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Doxalemzoparlimab | Nuvalent | Approved | AHR | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 |